-
Fierce Biotech2 weeks ago
Apogee eczema data drive hype to new peak as threat to Lilly and Sanofi becomes clear
Apogee Therapeutics has published phase 2 eczema data that suggest its anti-IL-13 antibody is a threat to Eli Lilly, Regeneron and Sanofi, prompting analysts to double...
-
Fierce Biotech2 weeks ago
FDA solicits feedback on controversial national priority voucher review pathway
The FDA has scheduled a public hearing for June 12 to hear input on the Commissioner’s National Priority Voucher program, which it introduced last June. So...
-
Fierce Biotech2 weeks ago
Sanofi returns to T-cell engager territory with $1.2B pact for phase 1-stage trispecific
Sanofi has returned to T-cell engager territory via an agreement to pay $180 million in the near term for a phase 1-stage trispecific antibody from Kali...
-
STAT News – Biotech2 weeks agoHer son needed a fecal transplant for a fearsome C. diff infection. Getting one required a tortuous journey
Her son had been sick for four months when Blanca Morales started asking about a transplant. It had started with a case of strep throat from...
-
STAT News – Biotech2 weeks agoOpinion: The AI push in health care is deepening medicine’s trust crisis
After OpenAI and Anthropic launched dedicated health care initiatives in January, a study published in February found that OpenAI’s ChatGPT Health had a 50% error rate, incorrectly recommending that care be delayed in emergency test cases...
-
Uncategorized2 weeks ago
Validated Mechanisms, Strong Data Beat Hype in Longevity Investing
Longevity is a long-standing buzzword in life sciences, but it now has staying power. The smart trajectory is to stop chasing aging as an abstract target...
-
Fierce Biotech2 weeks ago
Pfizer, Valneva blame low Lyme cases for phase 3 vaccine fail but still plan approval push
Pfizer and Valneva have blamed “fewer than anticipated” Lyme disease cases for the failure of their phase 3 trial to hit its key goal. But the...
-
Uncategorized2 weeks ago
Powering the Next Wave of Cell Therapy: From iPSC-Derived Cells to In Vivo Reprogramming
As cell therapy advances toward clinical reality, iPSC-derived cellular products, in vivo reprogramming strategies, and manufacturing-ready reagent platforms are reshaping regenerative medicine and oncology. Recombinant antibodies...
-
Uncategorized2 weeks ago
Gene Therapies for Hearing Loss Strike an Encouraging Note in Embattled Modality
Eli Lilly and Regeneron are leading the push to treat congenital deafness with gene therapies, seeking a piece of a potential billion-dollar market and banking on...
-
Uncategorized2 weeks ago
9 Months In, FDA’s New Priority Voucher Program Still Clouded With Uncertainty
The FDA’s Commissioner’s National Priority Voucher program, unveiled in June 2025, is “shrouded in secrecy,” Democratic representative Jake Auchincloss said last month, as regulatory and biopharma...
Terns rebuffed a higher bid before selling to Merck
